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Introduction
Loss of function of the p53 tumor suppressor protein plays an important role in the etiology of a wide range of cancers. Since many neoplastic cells undergo cell-cycle arrest or apoptosis following restoration of wild-type p53 function, several cancer gene therapy programs have the goal of re-establishing wild-type p53 expression in tumors. At present, assessment of in vivo p53 transduction efficiency is an unsolved problem, especially in the clinical setting. Several parameters are of interest, such as the efficiency of infection (the percentage of cells taking up the virus), the efficiency of viral gene expression (the number of p53 transcripts per viral genome) as well as the responsiveness of the cell to p53 (for example, the number of p21 or bax transcripts per viral p53 transcript). The simplest measure of transduction efficiency is the number of viral p53 transcripts per cellular p53 transcript, and this measure is particularly interesting given the potential for transdominance of endogenous mutant p53 over transduced wild-type p53 through formation of heterotetramers, a phenomenon which could abrogate the therapeutic effect of the transduced wild-type protein. It is possible to quantify relative transduction efficiency by Northern analysis of differences in size of the exogenous and endogenous p53 mRNA, but this is technically difficult with biopsies and it does not distinguish endogenous wild-type from mutant p53 alleles. 1 Immunoprecipitation with conformation-specific monoclonal antibodies can distinguish some mutants from wild-type p53, but fails to distinguish endogenous from exogenous wild-type p53, and the technique is too insensitive for use with clinical samples. 2 An alternative is to look for evidence of induction of p53 target genes, such as p21. 3 Unfortunately, p21 levels are known to vary widely in a p53-independent manner, for example upon differentiation in p53-null mice, and this variation can have a profound effect on outcomes relevant to gene therapy, such as apoptosis induction. 4, 5 The p21 response to p53 is further complicated by negative feedback of MDM2 on p53. 6 A more general problem is that since the p21 in both transduced and untransduced cells comes from the same locus it is formally impossible to distinguish virally induced from background p21 production. An attractive option would be to use immunohistochemical staining to visualize simultaneously p53, p21 and viral proteins (for example, terminal protein). While this approach can provide useful spatial information, it is not quantitative, does not distinguish endogenous from exogenous p53, wild-type from mutant p53 or background from induced p21, and multiple label staining of clinical samples is technically difficult.
In this article, we present a quantitative method applicable to small clinical samples which monitors the relative expression of transduced and endogenous p53 transcripts. The method is based on an assay which tests the ability of human p53 to activate transcription in vivo in yeast. 7 The transcription reporter is the ADE2 gene expressed from a p53-responsive promoter. Hence, colonies containing wild-type p53 are white, and colonies containing mutant p53 are red. Since human p53 cDNA PCR products are cloned directly in the reporter yeast strain by homologous recombination without intermediate bacterial cloning steps, the percentage of red yeast colonies accurately reflects the mutant p53 mRNA content of the starting material. To monitor transduction efficiency, primers specific for the viral and endogenous p53 mRNA are used for reverse transcription, and the yeast assay is used to generate quantitative data on mutant p53 cDNA content. We present a model which allows transduction efficiency to be extracted from these data, and the limits of this approach in a clinical setting are discussed.
Results

Selectivity of RT primers for cellular and viral p53
To distinguish endogenous from virally encoded p53 transcripts, two different primers were used for reverse transcription ( Figure 1 ). One primer, RT-1, anneals to a sequence in the p53 open reading frame 44-55 bases before the stop codon, the other, RT-2, anneals to a region of the p53 3′-untranslated region which is present only in the endogenous transcript (81-94 bases after the stop codon). Consequently, RT-PCR with RT-1 amplifies all p53 transcripts whereas RT-2 only amplifies cellular transcripts.
RNA from two untreated glioblastoma cell lines (SF-188 and U251MG) tested by yeast functional assay gave 100% red colonies with both RT primers. Sequence analysis of plasmids recovered from red colonies revealed homozygous p53 mutations in both cell lines (codon 266 GGA → GAA, Gly → Glu in SF-188 cells and codon 273 CGG → CAG, Arg → Gln in U251MG cells). As expected following infection with Ad-luc virus both cell lines again gave 100% red colonies with both RT primers. Functional assays using RT-1 after infection of SF-188 and U251MG cells with Ad-p53 virus at a MOI of 0.1 gave 66 and 19% red colonies, respectively ( Figure 2 ). In contrast, RT-2 gave 100% red colonies with both cell lines after Ad-p53 infection: this demonstrates that RT-2 can correctly distinguish cellular from viral p53 transcripts.
Apparent transduction efficiencies and p21 mRNA induction Provided the transduction efficiency is under 10, we can calculate an apparent transduction efficiency, 0 (see appendix for details). If P1 is the ratio of white to red colonies with RT-1, and P2 the ratio of white to red colonies with RT-2, then 0 = [P1 − P2]/[1 + P2]. With SF-188 this gives an apparent transduction efficiency of 0.5, and with U251MG an efficiency of 4.
To confirm that these values represent biologically relevant measures of transduction efficiency, the p21 mRNA level was analyzed by Northern blotting before and after Ad-p53 infection. If the transduced p53 is biologically active in the cell it should activate p21 transcription. 8 As shown in Figure 3 , the induction of p21 mRNA matched the calculated apparent transduction efficiencies for both cell lines.
Normal p53 mRNA and apparent transduction efficiencies To model the situation where there is a mixed population of infected cells, and thus P2 is not zero, functional assays were performed on HUG31 astrocytoma cells, which are heterozygous for a codon 161 mutation (GCC → GGC, Ala → Gly). 9 Since the wild-type and mutant alleles are equally expressed, one can model the relationship between MOI and calculated transduction efficiency in a situation where exactly half the cells can be considered normal and half tumoral, but all have an equal probability of infection. This was confirmed by the yeast assay of RNA from this cell line which gave approximately 50% red colonies. In principle, therefore, P2 should always be 1.0, whereas P1 should increase progressively with MOI. In practice, the observed P2 values were close to 1.0 at all except the highest MOI ( Table 1 ). The calculated transduction efficiencies increased as viral input increased, but the relationship was non-linear at extremes of MOI.
Another situation where a sample might contain a population of cells resistant to infection, was modelled by adding RNA from normal cells after the infection. This could represent the situation if, say, vascular cells were resistant to infection. On theoretical grounds it should produce a linear fall in the apparent transduction efficiency, although the effect should be modest unless the fraction of uninfected cells exceeds 50% (see Appendix for details). To test how normal cell-derived wildtype p53 mRNA influenced the result in practice, variable amounts of RNA from cells wild-type for p53 were mixed with RNA from Ad-p53 infected U251MG cells. The apparent transduction efficiency fell upon addition of normal RNA, although the difference was small ( Table 2 ).
Discussion
In this paper, we have tested a new method to measure transduction efficiency of adenovirus-mediated wild-type p53 transduction, using yeast p53 functional assay which permits quantitative scoring of mutant p53 transcripts. The endogenous p53 mRNA and adenovirus-derived p53 mRNA could be distinguished by priming reverse-transcription with two different p53-specific primers. Using a mathematical model for the transcripts distinction, we were able to calculate the apparent transduction efficiency which was expressed as a ratio of transduced p53 mRNA to endogenous mRNA. This method was applied to the two cell lines which harbored homozygous mutant p53. The calculated apparent transduction efficiency showed a correlation with induction of p21 expression measured by Northern blotting. This suggests that the yeast approach provides a biologically meaningful assay of transduction efficiency. It should be noted, however, that target gene induction is not generally a useful measure of transduction efficiency because it depends on many other factors, such as p53-independent regulation of transcription and MDM2 repression of p53-dependent transcription in different cell types.
Homozygous mutant cell lines, where P2 is zero, provide a simple test system but they do not reflect the true complexity in a clinical setting. Two important factors are missing: first, the sample will contain a mixture of infected normal (eg stromal) cells and infected tumor cells; and second, the sample may contain a heterogeneous mixture of infected and resistant cells (note that 
in yeast. Exogenous and endogenous p53 are distinguished by priming reverse transcription with two p53-specific primers, one of which (RT-2) lies in the p53 3′-untranslated region which is absent from the viral transcripts. The transduction efficiency can be calculated from the difference in the mutant p53 content (ratio of white to red yeast colonies) with the two primers (see appendix for details).
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Figure 2 Yeast assay results: (a) with RT-1 primer and (b) with RT-2 primer for Ad-p53-transduced SF-188 cells; (c) with RT-1 primer and (d) with RT-2 primer for Ad-p53-transduced U251MG cells.
Figure 3 Northern blot analysis for p21 induction in the transduced SF-188 and U251MG cells. Luc, luciferase-control virus; p53, Ad-p53 virus.
in both cases P2 is non-zero). Two experiments were performed to address these concerns. First, HUG-31 cells with a heterozygous mutant p53 were transduced with adenovirus at different MOI, to simulate the situation where there is a mixed population of infected cells. The observed P2 values were close to 1.0 at all except the highest MOI ( Table 1 ). The most likely explanation for this departure at high MOI is viral DNA HUG31 astrocytoma cells harboring a hemizygous 161Gly mutation were treated at different MOI of Ad-p53 virus, and RNA was extracted 24 h after infection and treated with DNase I as described in Materials and methods. The RNA was then reverse-transcribed with RT-1 and RT-2 primers which anneal to both endogenous and viral p53 and to only endogenous p53 mRNA, respectively. PCR-amplified RT-1-and RT-2-primed cDNA were cotransfected into the yeast reporter strain (yIG397) with the linearized p53 expression vector pSS16. After 48 h of culture, the red and white colonies were counted to calculate P1 (ratio of white to red colonies with RT-1), P2 (the ratio with RT-2), and the apparent transduction efficiency 0 (=
contamination, despite the extensive DNase I treatment of the purified RNA. The calculated transduction efficiencies increased as viral input increased, but the relationship became non-linear at extremes of MOI. At the lowest MOI this is probably caused by around 10% uncertainty in the measurement of P2, while the difficulty at higher MOI can be attributed to an irreducible background of red colonies due to RT-PCR mutations (which introduces large errors in P1 when P1 is Ͼ10) and contamination with viral DNA (which tends to reduce 0 through an effect on P2).
The second concern, that a sample might contain a population of cells resistant to infection, was modelled by adding RNA from normal cells after the infection. This could represent the situation if, say, vascular cells were resistant to infection. On theoretical grounds it should produce a linear fall in the apparent transduction efficiency, although the effect should be modest unless the fraction of uninfected cells exceeds 50% (see appendix for details). In practice, the apparent transduction efficiency fell upon addition of normal RNA, although the difference was small (Table 2 ). This no doubt partly reflects the lower abundance of p53 mRNA in the normal sample than in the U251MG sample, but since p53 mRNA levels are higher in growing than arrested cells, it plausibly reflects the likely situation in vivo.
In conclusion, we have shown that the yeast p53 functional assay can provide information about adenoviral transduction efficiency. The relationship between real transduction efficiency and calculated transduction efficiency is linear in a certain range of MOI. This does not limit the range of application of this assay. The assay may be used at extremes of 0 , where it can be used to make general statements about success ( 0 more than 10) or failure ( 0 less than 0.5) of gene transfer. The attempt of wild-type p53 transfer into a tumor has two major aims; one is directly to kill tumor cells through p53-mediated apoptosis and another to modulate gene expression under p53's control for sensitization to chemotherapy and/or radiotherapy. 10, 11 Highest transduction efficiency is needed in the former case. In the latter, the quantitative measurement should certainly be necessary where 0 takes a modest value, in other words, the amount of virus-derived p53 transcripts is comparable to the expression level of mutant p53. The assay will provide useful information in such a situation. Since successful treatment with gene therapy depends upon the delivery of the vector throughout the tumor, monitoring of transduction efficiency at the periphery of the tumor is always the critical issue rather than the transduction efficiency adjacent to the needle track. We believe that the present method may help to address the issue by determining whether the transduction efficiency reaches the effective level, which is considered theoretically and practically to correspond to the range of the assay.
Since the goal of adenoviral wild-type p53 gene transfer is induction of tumor cell apoptosis, transactivation of bax gene, a critical player of p53-mediated apoptosis, 11 by the adenoviral p53 should be a good readout factor in assessing the effect of gene therapy. A combination of quantitative measurement for transactivated bax gene either at mRNA or protein levels with the present method may provide more useful information. Alternatively, the yeast functional assay would possibly test the ability of transduced adenoviral p53 to transactivate bax, by replacing the RGC sequences in the reporter with the p53-responsive element in the bax gene promoter. 7 Some issues remain to be addressed, particularly the possibility that cell-to-cell variation in transduction efficiency may render global measures of efficiency unhelpful. The most informative approach would be to combine quantitative analysis using the yeast assay with qualitative immunohistochemical analysis of the spatial distribution of virus infection. Since we routinely perform yeast assays and histological studies on separate halves of small endoscopic biopsies, there is no technical obstacle to performing comprehensive analyses which address both spatial and quantitative concerns about the efficiency of adenovirus-mediated p53 gene therapy in human subjects. 12 
Materials and methods
Glioblastoma cell lines
Two glioblastoma cell lines SF-188 and U251MG and an astrocytoma cell line HUG31 were maintained with Dulbecco's modified Eagle's medium supplemented with 0.1 mm l-glutamine, 0.1% NaHCO 3 , 100 U/ml penicillin-G and 10% fetal calf serum, at 37°C in a humidified 5% CO 2 atmosphere. 9, 13, 14 Adenovirus-mediated p53 gene transfer Monolayer cultures were infected with adenovirus expressing wild-type p53 at a MOI of 0.1 p.f.u. per cell using Ad-p53 virus as previously described. 10 Ad-Luc (luciferase) virus was used as a control. Total RNA was extracted 24 h after infection using Trizol reagent (Gibco BRL, Tokyo, Japan). Normal RNA was obtained from lymphocytes of a healthy individual.
Yeast p53 functional assay
The yeast functional assay is a modification of the method previously described. 7, 9 To eliminate contamination with viral DNA, total RNA harvested from infected cultures was digested with DNase I (Gibco BRL) then extracted with phenol-chloroform and precipitated with ethanol. M-MLV reverse transcriptase was primed with 25 pM of p53-specific oligonucleotides: RT-1 ( 5′-CGGGAGGTAGAC-3′) or RT-2 (5′-GCAAGCAAGGG TTC-3′). cDNA was PCR-amplified using the primers and conditions previously described. 9 Crude PCR product and linearized p53-expression vector (pSS16) were cotransfected into the yeast reporter strain (yIG397), which was then grown as previously described. 7 Red and white colonies were counted after 48 h culture at 30°C.
Northern blot analysis
A 495 bp fragment of p21 cDNA was amplified by RT-PCR (primers: forward 5′-ATGTCAGAACCGGCTGGG GATGTCCG-3′, reverse 5′-TTAGGGCTTCCTCTTGGA GAAGATCA-3′), subcloned into TA cloning vector (Invitrogen, Carlsbad, CA, USA) and subsequently released with EcoRI and 32 P-labeled to make a probe. RNA were electrophoresed on a formaldehyde/agarose gel and transferred to a nylon membrane (Hybond-N; Amersham, UK). This was prehybridized in Hybrisol I (Oncor, Gaithersburg, MD, USA), followed by hybridization with the p21 probe at 42°C overnight. As a control, the membrane was hybridized with a glyceraldehyde 3-phosphate dehydrogenase probe (G3PDH; Clontech, Palo Alto, CA, USA). The membrane was washed and exposed to Kodak X-omat AR (Kodak, Tokyo, Japan) film at −70°C for 4 to 24 h.
